Risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection are being elucidated. An HBV DNA concentration greater than 10 4 copies/mL is an especially strong predictor of risk in individuals aged 30 years or older, independent of the level of serum alanine aminotransferase (ALT). Other predictors of cancer are HBV genotype, with genotype C imparting an increased risk, and serum ALT values at least two times the upper limit of normal. Viral suppression with continuous lamivudine therapy reduces the risk of complications and delays progression of liver disease as long as response is maintained.
T he role of hepatitis B virus (HBV) as a risk factor for the development of hepatocellular carcinoma (HCC) is well established. Not every patient with HBV infection develops HCC; yet, the current guidelines issued by the American Association for the Study of Liver Diseases 1 recommend screening all patients who have HBV infection when they reach certain ages associated with increased risk. Improved identifi cation of risk factors specifi cally associated with the likelihood of developing HCC may spare some patients the burden of unnecessary testing. This article reviews up-to-date information that will help identify patients who are at risk of HCC based on factors with more specifi city than age, and considers whether treatment can alter their risk.
ASSESSING RISK
Several factors are associated with increased risk of developing HCC (see "Case: Hepatocellular carcinoma in a young woman," page S7):
An elevated serum alanine aminotransferase • (ALT) level signifi es the presence of active disease and increases risk, particularly if the ALT is persistently or intermittently elevated over years.
Persistently elevated alpha-fetoprotein • level is a refl ection of enhanced regenerative state in the liver; the increased rate of cell division increases the risk of mutation, leading to increased risk of HCC.
A low platelet count • suggests the presence of cirrhosis, which itself increases the risk of HCC.
Histologic risk factors • revealed at biopsy include dysplasia, geographic morphologic changes that suggest clonal populations of cells, and a positive stain for proliferating cell nuclear antigen.
Viral load •
(HBV DNA) is a signifi cant predictor of HCC; two recent large, prospective studies-the Haimen City study 2, 3 and the REVEAL-HBV (Risk Evaluation of Viral Load Evaluation and Associated Liver Disease/Cancer-Hepatitis B Virus) study 4 -support the importance of this risk factor.
Haimen City study
The Haimen City study involved 83,794 subjects aged 25 to 64 years at entry. 2, 3 The 2,763 subjects who were positive for hepatitis B surface antigen (HBsAg) were tested at baseline for viral load and followed for 11 years. The relative risk of mortality associated with a high viral load (HBV DNA ≥ 10 5 copies/mL) was 11.2; low viral load (HBV DNA < 10 5 copies/mL) had no signifi cant association with mortality ( Figure 1) . Nearly 20% of the study subjects with high viral load died of HCC.
The REVEAL-HBV study The 
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30 to 65 years old who were free of HCC at baseline. 4 Of these, 3,653 were seropositive for HBsAg and seronegative for antibodies to hepatitis C virus. Some 1,619 men and women had serum HBV DNA levels greater than or equal to 10 4 copies/mL at study entry. 4 A direct correlation was observed between baseline HBV DNA levels and the incidence of HCC. During a mean follow-up period of 11.4 years, there were 164 new cases of HCC. In a model that integrated baseline and follow-up HBV DNA levels, the cumulative incidence of HCC ranged from 1.3% of those with undetectable levels of HBV DNA to 14.9% of those with HBV DNA levels of 10 6 copies/mL or greater. The same association between viral load and incidence of HCC was evident in patients who upon study entry had normal ALT levels and were hepatitis B e antigen (HBeAg) negative, a group previously considered to be inactive carriers of HBV.
The incidence of HCC was higher in the subjects with persistent viremia than in those whose viral load decreased over time, representing a biologic gradient of risk. Compared with the reference group (baseline HBV DNA < 10 4 copies/mL), the adjusted relative risk was nine times greater in those who maintained HBV DNA levels of 10 5 copies/mL or greater.
Genotype further defi nes risk
In addition to viral load, genotype may further defi ne the risk of HCC in HBV carriers aged 30 years or older. In a nested case-control study, genotype C was associated with fi vefold increased risk of HCC compared with other genotypes. 5 Consistent with other studies, the risk of HCC increased with increasing viral load.
Caveats to the viral load-HCC link
The association between viral load and the development of HCC applies to patients aged 30 years or older, the subjects of the aforementioned studies. Younger patients who present with a high viral load and are HBeAg positive are likely to be in an immune-tolerant phase of HBV infection. Among patients aged 30 years or older, the association between viral load and HCC applies to HBeAgpositive as well as HBeAg-negative status. The longer the HBeAg-positive state is maintained, the greater the risk of developing cirrhosis and HCC, which is a refl ection of active disease over a prolonged period. The association applies equally to patients with normal or elevated ALT levels. A risk nomogram is being developed that will help identify patients at highest risk of HCC. 
PREVENTING HEPATOCELLULAR CARCINOMA
were associated with the highest risk of development of complications.
Interestingly, an ALT level greater than six times the ULN was associated with a signifi cantly lower risk of liver complications. The speculation is that this phenomenon represents inactivation of disease following HBeAg seroconversion.
VIRAL LOAD SUPPRESSION LIMITS DISEASE PROGRESSION
Disease activity may fl are during the natural course of chronic HBV infection, and repeated episodes may lead to progressive fi brosis, cirrhosis, and end-stage liver disease, as well as HCC. Patients whose cirrhosis has progressed to end-stage liver disease are candidates for transplant.
Continuous antiviral therapy with lamivudine has been shown to dramatically reduce the risk of complications and disease progression in patients with chronic HBV infection. In a placebo-controlled trial of 651 patients with chronic HBV infection and advanced fi brosis or cirrhosis, those randomized to lamivudine who remained sensitive to the drug had a 7.8% risk of complications over approximately 3 years, compared with a 17.7% risk in the patients randomized to placebo. 8 The difference was signifi cant and sizeable enough that the study was terminated after a mean duration of 32.4 months. Patients who developed resistance to lamivudine, caused by a mutation in HBV (YMDD mutation, a sign of lamivudine resistance), lost the protection provided by viral suppression.
The risk of disease progression to cirrhosis or HCC was also signifi cantly lower among HBeAg-positive patients without cirrhosis who were treated with lamivudine for a median of 89.9 months compared with placebo, Yuen et al found. 9 As in other studies, patients in whom the YMDD mutation developed lost the protection of viral suppression.
In a retrospective study, Di Marco et al 10 also found that a loss of response to lamivudine was associated with higher risk of development of HCC, whereas patients who maintained a response to lamivudine were much less likely to develop progressive disease. The authors found that cirrhosis and loss of antiviral response were independently related to mortality and development of HCC.
SUMMARY
Patients with HBV are at risk for cancer, and the risk factors can be identifi ed.
Although not yet fully evaluated, awareness of these factors will make the screening process more effi cient and less burdensome than current guidelines recommend. The publication and eventual validation of a risk nomogram will facilitate the determination of risk. An especially strong predictor of adverse outcomes, including HCC, is HBV DNA concentration higher than 10 4 copies/mL, as shown by two recent large studies; further, investigators observed a correlation between HBV DNA level and incidence of HCC.
Antiviral therapy has dramatically reduced the risk of complications and progression of HBV infection. Those who develop resistance to therapy lose the protection provided by viral suppression. Morris Sherman, MD, PhD: I believe that you're referring to a recent study in which microarray technology was used to identify patients at risk for the development of a de novo tumor after a resection of the fi rst tumor.
DISCUSSION
11 Liver tissue surrounding the tumor was analyzed by microarray technology, and gene expression profi ling accurately predicted the development of a new tumor in another part of the liver more than 2 years later. This discovery suggests the presence of a fi eld defect, or a propensity for the development of new tumors in a damaged organ. Patients who have a fi eld defect identifi ed by the microarray technique are at much higher risk of developing a subsequent cancer. These patients might be candidates for liver transplant despite apparent surgical cure of their HCC. However, because the subsequent liver malignancy occurs some time later and is a new primary tumor, the need for transplant is less urgent than it is for a patient with a progressive hepatoma, for example. Pierre M. Gholam, MD: Do you consider ethnicity in addition to age, viral load, and other factors in your decision to screen patients for HCC? Dr. Sherman: We traditionally think of ethnicity as a major factor because HBV is concentrated in Asian and African populations. I'm not entirely sure whether ethnicity or the viral genotypes are more important, because the viral genotypes are distributed along ethnic lines. We know that genotypes B and C, which are common in the Far East, are associated with a high rate of progressive liver disease. Genotype D, observed mainly in Middle Eastern and Greek populations, is associated with a much higher rate of progressive liver disease than genotypes common in Western Europe and most of North America. I believe that genotype should be a factor in decisions to screen.
Robert G. Gish, MD:
In your case presentation you described the aspartate aminotransferase (AST) and ALT as being normal. New criteria defi ne an AST/ALT S9 SHERMAN of 20 as being "healthy" for a woman. I like the word "healthy" better than "normal." How would you have described those test results to the patient? Dr. Sherman: I would have told her that although her AST and ALT levels were within the laboratory reference range, ideally for a young woman the ALT should be closer to 20 U/L. Her actual levels were at least twice the upper range of ideal, and therefore, I believe a biopsy to determine the extent of injury in the liver would be important.
Tram T. Tran, MD:
Are there any new serum markers for liver cancer that have promise?
Dr. Sherman: The problem with serum markers, or biomarkers in general, is the confusion over their intended use, such as for screening, risk stratifi cation, or diagnosis.
I assume that your question refers to their potential use in screening, and so far none of the existing biomarkers is adequate to fi nd small tumors. For screening purposes, you ideally want to fi nd tumors that are 2 cm or smaller, and none of the biomarkers is effi cient with those small tumors. A biomarker is not needed to identify tumors that are 5 or 6 cm.
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